Efficacy Study of Oral Seliciclib to Treat Non-Small Cell Lung Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

187

Participants

Timeline

Start Date

August 9, 2006

Primary Completion Date

March 3, 2009

Study Completion Date

April 7, 2009

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

seliciclib

1200 mg bid x 3 days every 2 weeks

DRUG

placebo

1200 mg bid x 3 days every 2 weeks

Trial Locations (20)

10032

Columbia Presbyterian Medical Center, New York

15232

University of Pittsburg Cancer Institute, Pittsburgh

17033

Penn State Milton S. Hershey Medical Center, Hershey

21201

University of Maryland, Greenebaun Cancer Center, Baltimore

24541

Danville Hematology Oncology, Danville

34652

Pasco Hernando Oncology, New Port Richey

37232

Vanderbilt University Medical Center, Nashville

38017

The Family Cancer Center, Collierville

60612

Rush University Medical Center, Chicago

60637

The University of Chicago, Chicago

68198

Nebraska Medical Center, Omaha

75230

Center for Oncology Research and Treatment, Dallas

75701

East Texas Medical Center, Tyler

78705

Southwest Regional Cancer Center, Austin

85724

Arizona Cancer Center, Tucson

87109

New Mexico Oncology Hematology Consultants, Albuquerque

89106

Nevada Cancer Research Foundation, Las Vegas

89502

VA Sierra Nevada Health Care System, Reno

92708

Pacific Coast Hematology Oncology Group, Fountain Valley

02115

Dana Farber Cancer Institute, Boston

Sponsors
All Listed Sponsors
lead

Cyclacel Pharmaceuticals, Inc.

INDUSTRY

NCT00372073 - Efficacy Study of Oral Seliciclib to Treat Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter